Global Influenza Treatment Market is valued approximately USD 5.84 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.18% over the forecast period 2023-2030. Influenza treatment refers to the therapeutic interventions employed to alleviate the symptoms and complications associated with influenza, a highly contagious respiratory viral infection commonly known as the flu. The primary goals of influenza treatment are to reduce the severity and duration of symptoms, prevent complications, and limit the spread of the virus. The Influenza Treatment market is expanding because of factors such as increased prevalence of contagious respiratory illness, emerging prevalence of seasonal flu and rising drug approval activities.

As per the CDC, the impact of influenza in the United States is substantial, with an estimated 27 to 54 million cases, 300,000 to 650,000 hospitalizations, and 19,000 to 58,000 deaths annually between 2022 and 2023. Preliminary data also reveals around 9 million symptomatic cases, 4 million medical visits, 100,000 hospitalizations, and 5,000 deaths from 2021 to 2022. These figures underscore the significant public health challenge posed by influenza, emphasizing the need for effective preventive measures and treatments to mitigate its impact on individuals and healthcare systems. Thus rising prevalence of seasonal flu is driving the market growth. In addition, rising investment in research and development activities and increased public awareness about the severity of influenza is creating new opportunities for the market growth. However, the high cost of Influenza Treatment stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Influenza Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising disease prevalence, rising drug development activities in the region. Asia Pacific is expected to grow at a fastest rate during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for durg development, rising healthcare expenditure, and active participation of government and in the market space.

Major market player included in this report are:
NATCO Pharma Limited
Novartis AG
F. Hoffmann-La Roche Ltd
BioCryst Pharmaceuticals, Inc.
Sanofi
GSK plc.
Viatris Inc. (MYLAN)
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company, Limited.
AstraZeneca
Recent Developments in the Market:
In July 2023, Shionogi & Co., Ltd. has disclosed the submission of a supplemental New Drug Application (sNDA) for Xofluza. This application pertains to the pediatric population, specifically for children aged 5 to 12 years, and seeks approval for the use of Xofluza in both post-exposure prophylaxis and the treatment of influenza virus infections.
In April 2023, Nanjing Zenshine Pharmaceuticals revealed positive outcomes from the phase II trials of ZX-7101A, specifically designed to address acute uncomplicated influenza in adults
Global Influenza Treatment Market Report Scope:
Historical Data: 2020 - 2021
Base Year for Estimation: 2022
Forecast period: 2023-2030
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Treatment, Rout of Administration, Distribution Channel, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:
Peramivir
Zanamivir
Baloxavir Marboxil
Oseltamivir Phosphate
Others
By Route of Administration:
Oral
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa